Retrospective analysis of pembrolizumab-related adverse reactions and death outcomes based on the FAERS database
The serious adverse reactions in cancer patients treated with Pembrolizumab are closely related to patient individual characteristics and cancer types. It is necessary to strengthen the monitoring of high-risk groups such as the elderly in clinical treatment to reduce the risk of fatal outcomes.
Authors
- Ying Huang (ORCID: https://orcid.org/0000-0003-0543-0256)
- Dedong Cao (ORCID: https://orcid.org/0000-0002-5777-4176)
- Nan Zhao (ORCID: https://orcid.org/0000-0003-3981-8371)
- Huilin Xu (ORCID: https://orcid.org/0000-0002-7675-8374)
- Han Hu (ORCID: https://orcid.org/0000-0001-7604-4008)
Institutions
- Wuhan University (CN)
- Fifth Hospital In Wuhan (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1186/s12885-025-14342-2
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- U.S. Food and Drug Administration